NASDAQ:EDIT - Editas Medicine Stock Price, News, & Analysis

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

Editas Medicine Inc (NASDAQ:EDIT) issued its quarterly earnings results on Tuesday, May, 7th. The company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.57) by $0.03. The company earned $2.07 million during the quarter, compared to analyst estimates of $7.62 million. Editas Medicine had a negative return on equity of 47.64% and a negative net margin of 359.93%. The company's revenue was down 47.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.67) earnings per share. View Editas Medicine's Earnings History.

Editas Medicine is scheduled to release their next quarterly earnings announcement on Monday, August 5th 2019. View Earnings Estimates for Editas Medicine.

9 brokerages have issued 1 year target prices for Editas Medicine's shares. Their forecasts range from $30.00 to $55.00. On average, they anticipate Editas Medicine's stock price to reach $40.25 in the next twelve months. This suggests a possible upside of 75.1% from the stock's current price. View Analyst Price Targets for Editas Medicine.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Editas Medicine.

Press coverage about EDIT stock has been trending somewhat negative on Wednesday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Editas Medicine earned a media sentiment score of -1.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future.

Some companies that are related to Editas Medicine include Spark Therapeutics (ONCE), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Iovance Biotherapeutics (IOVA), Aerie Pharmaceuticals (AERI), Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX), Regenxbio (RGNX) and Alector (ALEC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include Crispr Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), TransEnterix (TRXC), Portola Pharmaceuticals (PTLA), Alibaba Group (BABA), CA (CA), BlackRock (BLK) and Advanced Micro Devices (AMD).

(EDIT) raised $100 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

Editas Medicine's stock is owned by a number of of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (9.26%), BlackRock Inc. (7.70%), Morgan Stanley (3.81%), FMR LLC (1.58%), Nikko Asset Management Americas Inc. (1.51%) and Sumitomo Mitsui Trust Holdings Inc. (1.47%). Company insiders that own Editas Medicine stock include Andrew A F Hack, Boris Nikolic, Charles Albright, Gerald Frank Cox, Jessica Hopfield, Katrine Bosley, Kevin Bitterman and Vickesh Myer. View Institutional Ownership Trends for Editas Medicine.

EDIT stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, JPMorgan Chase & Co., Trexquant Investment LP, Capital Advisors Inc. OK, Fiduciary Trust Co., Crestwood Advisors Group LLC, Morgan Stanley and First Trust Advisors LP. Company insiders that have sold Editas Medicine company stock in the last year include Andrew A F Hack, Charles Albright, Katrine Bosley and Vickesh Myer. View Insider Buying and Selling for Editas Medicine.

EDIT stock was acquired by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Great Lakes Advisors LLC, BlackRock Inc., Renaissance Technologies LLC, Man Group plc and SHANDA ASSET MANAGEMENT HOLDINGS Ltd. Company insiders that have bought Editas Medicine stock in the last two years include Boris Nikolic, Gerald Frank Cox and Jessica Hopfield. View Insider Buying and Selling for Editas Medicine.

Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of EDIT stock can currently be purchased for approximately $22.99.

Editas Medicine has a market capitalization of $1.13 billion and generates $31.94 million in revenue each year. The company earns $-109,950,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis. Editas Medicine employs 133 workers across the globe.

The official website for Editas Medicine is http://www.editasmedicine.com/.

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at 617-401-9000 or via email at [email protected]